Vertex Pharmaceuticals Email Format

Biotechnology ResearchMassachusetts, United States5001-10000 Employees

Vertex is a global biotechnology company headquartered in Boston, Massachusetts, focused on translating scientific innovation into medicines for people with serious diseases. Its efforts have yielded advancements in cystic fibrosis, sickle cell disease, transfusion-dependent beta-thalassemia, and acute pain, with ongoing clinical and research programs in these areas. The company maintains research and development sites and commercial offices around the world.

Vertex pursues a broader pipeline across additional serious conditions where it applies insights into causal human biology, including acute and neuropathic pain, kidney diseases such as APOL1-mediated kidney disease and IgA nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes, and myotonic dystrophy type 1. In June 2026, Vertex launched Casgevy, a gene-editing therapy for sickle cell disease and transfusion-dependent beta-thalassemia, expanding beyond cystic fibrosis, and introduced Journavx for acute pain. The company is a large, multinational organization with a workforce distributed globally and a history of industry recognition as a top place to work.

Sign up for free to view info

Company overview Employee directory